Sagimet Biosciences Inc.
SGMT Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$10.42
KIRA · Stoqly’s AI analyst, in plain words
- Sagimet Biosciences Inc. lost $51.0M in fiscal 2025.
Market cap
$553M
P/E
—
Revenue
—
Net income
−$51.0M
Free cash flow
—
Operating margin
—
Sagimet Biosciences Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$51.0M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Sagimet Biosciences Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 11, 2026
- Legal name
- Sagimet Biosciences Inc.
- CIK
- 0001400118
Sagimet Biosciences Inc. · SGMT
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | — | $2.0M | — | — |
| Operating margin | — | −1,537.0% | — | — |
| Net income | −$30.5M | −$27.9M | −$45.6M | −$51.0M |
| Net margin | — | −1,393.8% | — | — |
| Diluted EPS | −$165.20 | −$2.66 | −$1.45 | −$1.58 |
| Cash | ||||
| Cash from operations | −$24.5M | −$23.8M | −$42.4M | −$45.7M |
| Share count change | — | 5,566.5% | 199.7% | 3.2% |
| Debt and strength | ||||
| Cash and short-term investments | $32.3M | $94.9M | $151M | $113M |
| Shareholders' equity | −$187M | $91.1M | $156M | $111M |
| Current ratio | 6.2x | 17.1x | 34.3x | 22.8x |
| Returns and quality | ||||
| Return on equity | — | — | −36.9% | −38.2% |
| Return on tangible equity | — | −30.6% | −29.2% | −45.8% |
| Altman Z'' | −59.4 | 12.5 | 34.5 | 16.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$4.9M
5 insiders
Of sales under plans
86%
$4.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Sagimet Biosciences Inc. · SGMT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.42 a share, the company is worth $553M.
Source: SEC EDGAR XBRL filings (CIK 0001400118). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.